1-3 of 3
Timothy J. Purwin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis

Free
Dan A. Erkes, Weijia Cai, Ileine M. Sanchez, Timothy J. Purwin, Corey Rogers, Conroy O. Field, Adam C. Berger, Edward J. Hartsough, Ulrich Rodeck, Emad S. Alnemri, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2020) 10 (2): 254–269.
https://doi.org/10.1158/2159-8290.CD-19-0672
Published: 05 February 2020
View articletitled, Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
Open the PDF for Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis in another window
Includes: Supplementary data
Journal Articles

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

Free
Jessica L.F. Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Adam Ertel, Paolo M. Fortina, Ines Kleiber, Kim HooKim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2018) 8 (12): 1654.
https://doi.org/10.1158/2159-8290.CD-18-1291
Published: 03 December 2018
View articletitled, Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
Open the PDF for Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms in another window
Journal Articles

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms

Free
Jessica L.F. Teh, Phil F. Cheng, Timothy J. Purwin, Neda Nikbakht, Prem Patel, Inna Chervoneva, Adam Ertel, Paolo M. Fortina, Ines Kleiber, Kim HooKim, Michael A. Davies, Lawrence N. Kwong, Mitch P. Levesque, Reinhard Dummer, Andrew E. Aplin
Journal: Cancer Discovery
Cancer Discov (2018) 8 (5): 568–581.
https://doi.org/10.1158/2159-8290.CD-17-0699
Published: 30 April 2018
View articletitled, In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
Open the PDF for In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms in another window
Includes: Supplementary data